Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group HoldingsHKSE:06998 +0.33%15 ROA % is 6.73% as of Dec. 2025, which is 3% below its 10-year median of 6.93. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, Edding Genor Group Holdings ranks better than 69.81% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Edding Genor Group Holdings's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$441 Mil.
Edding Genor Group Holdings's average Total Assets over the quarter that ended in Dec. 2025 was HK$6,551 Mil. Therefore, Edding Genor Group Holdings's annualized ROA % for the quarter that ended in Dec. 2025 was 6.73%.
The historical rank and industry rank for Edding Genor Group Holdings's ROA % or its related term are showing as below:
HKSE:06998'
s ROA % Range Over the Past 10 Years
Min: 6.73 Med: 6.93 Max: 7.13
Current: 6.73
During the past 2 years, Edding Genor Group Holdings's highest ROA % was 7.13%. The lowest was 6.73%. And the median was 6.93%.
HKSE:06998's ROA % is ranked better than 69.81% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.56
vs HKSE:06998: 6.73
Edding Genor Group Holdings (HKSE:06998) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings ROA % Chart
Edding Genor Group Holdings Annual Data
Trend
Dec24
Dec25
ROA %
7.13
6.73
Edding Genor Group Holdings Semi-Annual Data
Dec24
Dec25
ROA %
7.13
6.73
HKSE:06998 vs ZTS: ROA % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's ROA % distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Edding Genor Group Holdings (HKSE:06998) has a ROA % of 6.73% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Edding Genor Group Holdings and its competitors. This is near median its historical median of 6.93. Over the past decade, Edding Genor Group Holdings' ROA % has ranged from 6.73 to 7.13. According to the industry distribution chart, Edding Genor Group Holdings ranks #304 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Edding Genor Group Holdings' ROA % too high?
Edding Genor Group Holdings' current ROA % of 6.73% is near median its 10-year median of 6.93. Over the past 10 years, this metric has ranged from a low of 6.73 to a high of 7.13. The Drug Manufacturers industry median ROA % is 2.56. Edding Genor Group Holdings' value of 6.73% is 162.9% above this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #304 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #304 out of 1007 companies for ROA %. This puts Edding Genor Group Holdings in the upper half of its industry. The industry median ROA % is 2.56. Edding Genor Group Holdings' value of 6.73% is 162.9% above this benchmark. Historically, Edding Genor Group Holdings' own ROA % has ranged from 6.73 to 7.13 over the past decade. While the company's 10-year median is 6.93 vs. the industry median of 2.56, Edding Genor Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.56, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current ROA % of 6.73% is 162.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current ROA % is 6.73%, which is near median its own 10-year median of 6.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current ROA % of 6.73%. The current ROA % is 6.73%, which is near median its 10-year median of 6.93 and 162.9% above the Drug Manufacturers industry median of 2.56. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current ROA % is 6.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
